Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Marker Therapeutics Inc (MRKR)

34 + Investors. Track Smart Money conviction in MRKR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
1Q ▼
Buyers last Q
43%

Smart Money Signals — MRKR

Based on 34 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their MRKR positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 94% of 3.0Y peak

94% of all-time peak
34 funds currently hold this stock — 94% of the 3.0-year high of 36 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +10% more funds vs a year ago

fund count last 6Q
+3 new funds entered over the past year (+10% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 43% buying

13 buying17 selling
Last quarter: 17 funds reduced or exited vs 13 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~7 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 3 → 9 → 9 → 7. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

44% of holders stayed for 2+ years

■ 44% conviction (2yr+) ■ 24% medium ■ 32% new
15 out of 34 hedge funds have held MRKR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~7 new funds/quarter

3 → 3 → 9 → 9 → 7 new funds/Q
New funds entering each quarter: 3 → 9 → 9 → 7. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Deep conviction — 53% of holders stayed 2+ years

■ 53% veterans ■ 18% 1-2yr ■ 29% new
Of 34 current holders: 18 (53%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
📋

Smaller funds dominant — 11% AUM from top-100

11% from top-100 AUM funds
11 of 34 holders rank in the top 100 by AUM, but together hold only 11% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MRKR

In 2026 Q1, 13 hedge funds were net buyers of MRKR (7 opened a new position, 6 added to an existing one), while 17 reduced or exited (8 trimmed, 9 sold completely) — a 43% buyer ratio, indicating roughly balanced activity. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 34.

Hedge Fund Ownership: MRKR

How many hedge funds hold MRKR — quarterly history vs. share price
Quarterly hedge fund ownership of MRKR vs. share price

Market Analysis: MRKR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MRKR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Marker Therapeutics Inc (MRKR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MRKR has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 76d ago
MRKR
+6.2%
XLV
+4.9%

MRKR outperformed XLV by +1.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 31d ago
MRKR
-2.8%
XLV
+6.0%

Since the filing became public, MRKR outperformed XLV by -8.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

2 top-rated funds 0 high-conviction
Consensus
2.1
/ 10
breadth
×
Elite
0.1
/ 10
conviction
Hedge Fund Positioning: MRKR
34 + Investors

Track Smart Money conviction in MRKR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 34 36 -5.56%
13F Shares 4M 4M -3.55%
Total Value $5M $6M -15.87%
New Positions 7 9 -2
Increased Positions 6 11 -5
Closed Positions 9 5 +4
Reduced Positions 8 2 +6
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: MRKR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

34 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MRKR. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MRKR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Blue Owl Capital Holdings LP 0.19% 554,250 $721K
2 NEA Management Company, LLC 0.12% 1,625,678 $2.1M
3 Aisling Capital Management LP 0.09% 325,370 $423K
4 Invst, LLC 0.00% 29,000 $38K
5 Matrix Asset Advisors Inc/Ny 0.00% 15,000 $20K
6 Two Sigma Securities, LLC 0.00% 11,460 $15K
7 XTX Topco Ltd 0.00% 63,567 $83K
8 Ashton Thomas Private Wealth, LLC 0.00% 16,400 $21K
9 Renaissance Technologies LLC 0.00% 175,294 $228K
10 International Assets Investment Management, LLC 0.00% 2,000 $3K
11 Osaic Holdings, INC. 0.00% 93,121 $121K
12 Tower Research Capital LLC (TRC) 0.00% 3,137 $4K
13 Two Sigma Investments, LP 0.00% 61,001 $79K
14 Hrt Financial LP 0.00% 11,852 $15K
15 Vanguard Fiduciary Trust Co 0.00% 87,269 $113K
16 LPL Financial LLC 0.00% 83,047 $108K
17 Fifth Third Bancorp 0.00% 10,000 $13K
18 Hilltop National Bank 0.00% 73 —
19 Western Wealth Management, LLC 0.00% 368 —
20 Creative Planning 0.00% 17,312 $23K
21 Vanguard Capital Management LLC 0.00% 389,319 $506K
22 SBI Securities Co., Ltd. 0.00% 203 —
23 Susquehanna International Group, LLP 0.00% 48,780 $63K
24 UBS Group AG 0.00% 32,369 $42K
25 Jane Street Group, LLC 0.00% 36,303 $47K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Marker Therapeutics Inc (MRKR)

What does the Smart Money Trend signal show for MRKR?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their MRKR positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for MRKR?

More sellers than buyers — 43% buying: Last quarter: 17 funds reduced or exited vs 13 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for MRKR holders?

Smaller funds dominant — 11% AUM from top-100: 11 of 34 holders rank in the top 100 by AUM, but together hold only 11% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held MRKR?

44% of holders stayed for 2+ years: 15 out of 34 hedge funds have held MRKR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Marker Therapeutics Inc (MRKR) following the 2026 Q1 hedge fund 13F filings?

As of today, MRKR has moved -2.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -8.8%. Since the quarter end (March 31, 2026), MRKR has gained +6.2% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →